Morphic Holding, Inc.

NASDAQ:MORF

56.99 (USD) • At close August 15, 2024
Bedrijfsnaam Morphic Holding, Inc.
Symbool MORF
Munteenheid USD
Prijs 56.99
Beurswaarde 2,862,305,653
Dividendpercentage 0%
52-weken bereik 19.345 - 57
Industrie Biotechnology
Sector Healthcare
CEO Dr. Praveen P. Tipirneni M.D.
Website https://www.morphictx.com

An error occurred while fetching data.

Over Morphic Holding, Inc.

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of

Vergelijkbare Aandelen

National Research Corporation logo

National Research Corporation

NRC

21.71 USD

REGENXBIO Inc. logo

REGENXBIO Inc.

RGNX

11.48 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

52.51 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

19.1 USD

Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc.

TMCI

5.33 USD

Cerus Corporation logo

Cerus Corporation

CERS

2.02 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

41.12 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

5.04 USD

Procaps Group S.A. logo

Procaps Group S.A.

PROC

1.94 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)